JP2014088422A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014088422A5 JP2014088422A5 JP2014001693A JP2014001693A JP2014088422A5 JP 2014088422 A5 JP2014088422 A5 JP 2014088422A5 JP 2014001693 A JP2014001693 A JP 2014001693A JP 2014001693 A JP2014001693 A JP 2014001693A JP 2014088422 A5 JP2014088422 A5 JP 2014088422A5
- Authority
- JP
- Japan
- Prior art keywords
- delivery device
- transdermal delivery
- disposal system
- adhesive
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000037317 transdermal delivery Effects 0.000 claims 12
- -1 azo compound Chemical class 0.000 claims 11
- 239000000853 adhesive Substances 0.000 claims 7
- 230000001070 adhesive effect Effects 0.000 claims 7
- 239000000178 monomer Substances 0.000 claims 6
- 239000003999 initiator Substances 0.000 claims 5
- 239000013543 active substance Substances 0.000 claims 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims 3
- 239000003431 cross linking reagent Substances 0.000 claims 3
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims 3
- 229960001410 hydromorphone Drugs 0.000 claims 3
- 238000007789 sealing Methods 0.000 claims 3
- 239000000758 substrate Substances 0.000 claims 3
- DEXMFYZAHXMZNM-UHFFFAOYSA-N Narceine Chemical compound OC(=O)C1=C(OC)C(OC)=CC=C1C(=O)CC1=C(CCN(C)C)C=C(OCO2)C2=C1OC DEXMFYZAHXMZNM-UHFFFAOYSA-N 0.000 claims 2
- 238000004873 anchoring Methods 0.000 claims 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 2
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims 2
- 150000002118 epoxides Chemical class 0.000 claims 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 2
- 230000000415 inactivating effect Effects 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 229940005483 opioid analgesics Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- UVITTYOJFDLOGI-UHFFFAOYSA-N (1,2,5-trimethyl-4-phenylpiperidin-4-yl) propanoate Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)CC(C)N(C)CC1C UVITTYOJFDLOGI-UHFFFAOYSA-N 0.000 claims 1
- IJVCSMSMFSCRME-NOSXKOESSA-N (4r,4ar,7r,7ar,12bs)-3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol Chemical compound O([C@H]1[C@@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-NOSXKOESSA-N 0.000 claims 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 1
- IYNWSQDZXMGGGI-NUEKZKHPSA-N 3-hydroxymorphinan Chemical compound C1CCC[C@H]2[C@H]3CC4=CC=C(O)C=C4[C@]21CCN3 IYNWSQDZXMGGGI-NUEKZKHPSA-N 0.000 claims 1
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical group COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 claims 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 1
- 229920001651 Cyanoacrylate Polymers 0.000 claims 1
- IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 claims 1
- OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 claims 1
- OGDVEMNWJVYAJL-UHFFFAOYSA-N Ethylmorphine Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OCC OGDVEMNWJVYAJL-UHFFFAOYSA-N 0.000 claims 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 1
- ALFGKMXHOUSVAD-UHFFFAOYSA-N Ketobemidone Chemical compound C=1C=CC(O)=CC=1C1(C(=O)CC)CCN(C)CC1 ALFGKMXHOUSVAD-UHFFFAOYSA-N 0.000 claims 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 claims 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical group C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 claims 1
- ONBWJWYUHXVEJS-ZTYRTETDSA-N Normorphine Chemical compound C([C@@H](NCC1)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 ONBWJWYUHXVEJS-ZTYRTETDSA-N 0.000 claims 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims 1
- MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical compound O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 claims 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 229960001391 alfentanil Drugs 0.000 claims 1
- 230000003444 anaesthetic effect Effects 0.000 claims 1
- LKYQLAWMNBFNJT-UHFFFAOYSA-N anileridine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC1=CC=C(N)C=C1 LKYQLAWMNBFNJT-UHFFFAOYSA-N 0.000 claims 1
- 229960002512 anileridine Drugs 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000003474 anti-emetic effect Effects 0.000 claims 1
- 229940125683 antiemetic agent Drugs 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- RDJGWRFTDZZXSM-RNWLQCGYSA-N benzylmorphine Chemical compound O([C@@H]1[C@]23CCN([C@H](C4)[C@@H]3C=C[C@@H]1O)C)C1=C2C4=CC=C1OCC1=CC=CC=C1 RDJGWRFTDZZXSM-RNWLQCGYSA-N 0.000 claims 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims 1
- 229960001736 buprenorphine Drugs 0.000 claims 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 claims 1
- 229960001113 butorphanol Drugs 0.000 claims 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 1
- 150000007942 carboxylates Chemical class 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 229960004126 codeine Drugs 0.000 claims 1
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 claims 1
- 229950003851 desomorphine Drugs 0.000 claims 1
- INUNXTSAACVKJS-OAQYLSRUSA-N dextromoramide Chemical compound C([C@@H](C)C(C(=O)N1CCCC1)(C=1C=CC=CC=1)C=1C=CC=CC=1)N1CCOCC1 INUNXTSAACVKJS-OAQYLSRUSA-N 0.000 claims 1
- 229960003701 dextromoramide Drugs 0.000 claims 1
- 229960004193 dextropropoxyphene Drugs 0.000 claims 1
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims 1
- 229960003461 dezocine Drugs 0.000 claims 1
- VTMVHDZWSFQSQP-VBNZEHGJSA-N dezocine Chemical compound C1CCCC[C@H]2CC3=CC=C(O)C=C3[C@]1(C)[C@H]2N VTMVHDZWSFQSQP-VBNZEHGJSA-N 0.000 claims 1
- 150000004985 diamines Chemical class 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- 150000008049 diazo compounds Chemical class 0.000 claims 1
- 150000005690 diesters Chemical class 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 229960000920 dihydrocodeine Drugs 0.000 claims 1
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 claims 1
- 125000005442 diisocyanate group Chemical group 0.000 claims 1
- RHUWRJWFHUKVED-UHFFFAOYSA-N dimenoxadol Chemical compound C=1C=CC=CC=1C(C(=O)OCCN(C)C)(OCC)C1=CC=CC=C1 RHUWRJWFHUKVED-UHFFFAOYSA-N 0.000 claims 1
- 229950011187 dimenoxadol Drugs 0.000 claims 1
- QIRAYNIFEOXSPW-UHFFFAOYSA-N dimepheptanol Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(O)CC)C1=CC=CC=C1 QIRAYNIFEOXSPW-UHFFFAOYSA-N 0.000 claims 1
- CANBGVXYBPOLRR-UHFFFAOYSA-N dimethylthiambutene Chemical compound C=1C=CSC=1C(=CC(C)N(C)C)C1=CC=CS1 CANBGVXYBPOLRR-UHFFFAOYSA-N 0.000 claims 1
- 229950005563 dimethylthiambutene Drugs 0.000 claims 1
- 150000002009 diols Chemical class 0.000 claims 1
- SVDHSZFEQYXRDC-UHFFFAOYSA-N dipipanone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CC(C)N1CCCCC1 SVDHSZFEQYXRDC-UHFFFAOYSA-N 0.000 claims 1
- 229960002500 dipipanone Drugs 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- ZOWQTJXNFTWSCS-IAQYHMDHSA-N eptazocine Chemical compound C1N(C)CC[C@@]2(C)C3=CC(O)=CC=C3C[C@@H]1C2 ZOWQTJXNFTWSCS-IAQYHMDHSA-N 0.000 claims 1
- 229950010920 eptazocine Drugs 0.000 claims 1
- 150000002148 esters Chemical group 0.000 claims 1
- MORSAEFGQPDBKM-UHFFFAOYSA-N ethylmethylthiambutene Chemical compound C=1C=CSC=1C(=CC(C)N(C)CC)C1=CC=CS1 MORSAEFGQPDBKM-UHFFFAOYSA-N 0.000 claims 1
- 229950006111 ethylmethylthiambutene Drugs 0.000 claims 1
- 229960004578 ethylmorphine Drugs 0.000 claims 1
- CAHCBJPUTCKATP-FAWZKKEFSA-N etorphine Chemical compound O([C@H]1[C@@]2(OC)C=C[C@@]34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O CAHCBJPUTCKATP-FAWZKKEFSA-N 0.000 claims 1
- 229950004155 etorphine Drugs 0.000 claims 1
- 229960002428 fentanyl Drugs 0.000 claims 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims 1
- 229960000240 hydrocodone Drugs 0.000 claims 1
- 150000002432 hydroperoxides Chemical class 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 229910001869 inorganic persulfate Inorganic materials 0.000 claims 1
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 claims 1
- IFKPLJWIEQBPGG-UHFFFAOYSA-N isomethadone Chemical compound C=1C=CC=CC=1C(C(C)CN(C)C)(C(=O)CC)C1=CC=CC=C1 IFKPLJWIEQBPGG-UHFFFAOYSA-N 0.000 claims 1
- 229950009272 isomethadone Drugs 0.000 claims 1
- 229960003029 ketobemidone Drugs 0.000 claims 1
- RCYBMSQOSGJZLO-BGWNEDDSSA-N levophenacylmorphan Chemical compound C([C@]12CCCC[C@H]1[C@H]1CC3=CC=C(C=C32)O)CN1CC(=O)C1=CC=CC=C1 RCYBMSQOSGJZLO-BGWNEDDSSA-N 0.000 claims 1
- 229950007939 levophenacylmorphan Drugs 0.000 claims 1
- IMYHGORQCPYVBZ-UHFFFAOYSA-N lofentanyl Chemical group C1CN(CCC=2C=CC=CC=2)CC(C)C1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 IMYHGORQCPYVBZ-UHFFFAOYSA-N 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 229960000365 meptazinol Drugs 0.000 claims 1
- JLICHNCFTLFZJN-HNNXBMFYSA-N meptazinol Chemical compound C=1C=CC(O)=CC=1[C@@]1(CC)CCCCN(C)C1 JLICHNCFTLFZJN-HNNXBMFYSA-N 0.000 claims 1
- YEOTYALSMRNXLJ-UHFFFAOYSA-N metazosin Chemical compound C1CN(C(=O)C(C)OC)CCN1C1=NC(N)=C(C=C(OC)C(OC)=C2)C2=N1 YEOTYALSMRNXLJ-UHFFFAOYSA-N 0.000 claims 1
- 229960001797 methadone Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 229950007471 myrophine Drugs 0.000 claims 1
- GODGZZGKTZQSAL-VXFFQEMOSA-N myrophine Chemical compound C([C@@H]1[C@@H]2C=C[C@@H]([C@@H]3OC4=C5[C@]23CCN1C)OC(=O)CCCCCCCCCCCCC)C5=CC=C4OCC1=CC=CC=C1 GODGZZGKTZQSAL-VXFFQEMOSA-N 0.000 claims 1
- 229960000805 nalbuphine Drugs 0.000 claims 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 229960004300 nicomorphine Drugs 0.000 claims 1
- HNDXBGYRMHRUFN-CIVUWBIHSA-N nicomorphine Chemical compound O([C@H]1C=C[C@H]2[C@H]3CC=4C5=C(C(=CC=4)OC(=O)C=4C=NC=CC=4)O[C@@H]1[C@]52CCN3C)C(=O)C1=CC=CN=C1 HNDXBGYRMHRUFN-CIVUWBIHSA-N 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 229950011519 norlevorphanol Drugs 0.000 claims 1
- 229960004013 normethadone Drugs 0.000 claims 1
- WCJFBSYALHQBSK-UHFFFAOYSA-N normethadone Chemical compound C=1C=CC=CC=1C(CCN(C)C)(C(=O)CC)C1=CC=CC=C1 WCJFBSYALHQBSK-UHFFFAOYSA-N 0.000 claims 1
- 229950006134 normorphine Drugs 0.000 claims 1
- 239000003402 opiate agonist Substances 0.000 claims 1
- 150000001451 organic peroxides Chemical class 0.000 claims 1
- 229960002085 oxycodone Drugs 0.000 claims 1
- 229960005118 oxymorphone Drugs 0.000 claims 1
- 229940069533 paregoric Drugs 0.000 claims 1
- 239000008414 paregoric Substances 0.000 claims 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 claims 1
- 229960005301 pentazocine Drugs 0.000 claims 1
- 150000002978 peroxides Chemical class 0.000 claims 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 claims 1
- 229960000482 pethidine Drugs 0.000 claims 1
- LOXCOAXRHYDLOW-UHFFFAOYSA-N phenadoxone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CC(C)N1CCOCC1 LOXCOAXRHYDLOW-UHFFFAOYSA-N 0.000 claims 1
- 229950004540 phenadoxone Drugs 0.000 claims 1
- 229960000436 phendimetrazine Drugs 0.000 claims 1
- CFBQYWXPZVQQTN-QPTUXGOLSA-N phenomorphan Chemical compound C([C@]12CCCC[C@H]1[C@H]1CC3=CC=C(C=C32)O)CN1CCC1=CC=CC=C1 CFBQYWXPZVQQTN-QPTUXGOLSA-N 0.000 claims 1
- 229950011496 phenomorphan Drugs 0.000 claims 1
- 229960004315 phenoperidine Drugs 0.000 claims 1
- IPOPQVVNCFQFRK-UHFFFAOYSA-N phenoperidine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(O)C1=CC=CC=C1 IPOPQVVNCFQFRK-UHFFFAOYSA-N 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- ZXWAUWBYASJEOE-UHFFFAOYSA-N proheptazine Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)CCCN(C)CC1C ZXWAUWBYASJEOE-UHFFFAOYSA-N 0.000 claims 1
- XJKQCILVUHXVIQ-UHFFFAOYSA-N properidine Chemical compound C=1C=CC=CC=1C1(C(=O)OC(C)C)CCN(C)CC1 XJKQCILVUHXVIQ-UHFFFAOYSA-N 0.000 claims 1
- 229950004345 properidine Drugs 0.000 claims 1
- JCRIVQIOJSSCQD-UHFFFAOYSA-N propylhexedrine Chemical compound CNC(C)CC1CCCCC1 JCRIVQIOJSSCQD-UHFFFAOYSA-N 0.000 claims 1
- 229960000786 propylhexedrine Drugs 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 claims 1
- 229910052710 silicon Inorganic materials 0.000 claims 1
- 239000010703 silicon Substances 0.000 claims 1
- 229960004380 tramadol Drugs 0.000 claims 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000019195 vitamin supplement Nutrition 0.000 claims 1
- 239000004711 α-olefin Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38780002P | 2002-06-10 | 2002-06-10 | |
| US60/387,800 | 2002-06-10 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010158074A Division JP5507367B2 (ja) | 2002-06-10 | 2010-07-12 | 経皮送達デバイスに含有された活性薬剤の誤用を防止する、経皮送達デバイスの廃棄システム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014088422A JP2014088422A (ja) | 2014-05-15 |
| JP2014088422A5 true JP2014088422A5 (enExample) | 2014-07-24 |
| JP5898242B2 JP5898242B2 (ja) | 2016-04-06 |
Family
ID=29736367
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004510792A Expired - Fee Related JP4949625B2 (ja) | 2002-06-10 | 2003-06-10 | 経皮送達デバイスに含有された活性薬剤の誤用を防止する、経皮送達デバイスの廃棄システム |
| JP2010158074A Expired - Lifetime JP5507367B2 (ja) | 2002-06-10 | 2010-07-12 | 経皮送達デバイスに含有された活性薬剤の誤用を防止する、経皮送達デバイスの廃棄システム |
| JP2014001693A Expired - Fee Related JP5898242B2 (ja) | 2002-06-10 | 2014-01-08 | 経皮送達デバイスに含有された活性薬剤の誤用を防止する、経皮送達デバイスの廃棄システム |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004510792A Expired - Fee Related JP4949625B2 (ja) | 2002-06-10 | 2003-06-10 | 経皮送達デバイスに含有された活性薬剤の誤用を防止する、経皮送達デバイスの廃棄システム |
| JP2010158074A Expired - Lifetime JP5507367B2 (ja) | 2002-06-10 | 2010-07-12 | 経皮送達デバイスに含有された活性薬剤の誤用を防止する、経皮送達デバイスの廃棄システム |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20040033255A1 (enExample) |
| EP (4) | EP2298302A1 (enExample) |
| JP (3) | JP4949625B2 (enExample) |
| KR (2) | KR20110120358A (enExample) |
| CN (2) | CN100525767C (enExample) |
| AT (1) | ATE355061T1 (enExample) |
| AU (2) | AU2003251482A1 (enExample) |
| CA (1) | CA2488915C (enExample) |
| CY (1) | CY1107630T1 (enExample) |
| DE (1) | DE60312160T2 (enExample) |
| DK (1) | DK1513532T3 (enExample) |
| EA (1) | EA007240B1 (enExample) |
| ES (1) | ES2283812T3 (enExample) |
| IL (1) | IL165517A0 (enExample) |
| MX (1) | MXPA04012333A (enExample) |
| NO (1) | NO334455B1 (enExample) |
| NZ (1) | NZ537180A (enExample) |
| PT (1) | PT1513532E (enExample) |
| SI (1) | SI1513532T1 (enExample) |
| UA (1) | UA82194C2 (enExample) |
| WO (1) | WO2003103673A1 (enExample) |
| ZA (1) | ZA200409495B (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040202717A1 (en) * | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
| AU2004235794B8 (en) * | 2003-04-30 | 2009-07-23 | Purdue Pharma L.P. | Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer |
| US8790689B2 (en) * | 2003-04-30 | 2014-07-29 | Purdue Pharma L.P. | Tamper resistant transdermal dosage form |
| US7867511B2 (en) | 2004-01-23 | 2011-01-11 | Travanti Pharma Inc. | Abuse potential reduction in abusable substance dosage form |
| US8535711B2 (en) | 2004-01-23 | 2013-09-17 | Teikoku Pharma Usa, Inc. | Medication disposal system |
| PT2351555T (pt) * | 2004-02-23 | 2016-11-29 | Euro Celtique Sa | Dispositivo para a administração transdérmica de opióides resistente ao abuso |
| US20060045897A1 (en) * | 2004-08-27 | 2006-03-02 | Aso Corporation | Occlusive articles for wart treatment |
| AU2005284908B2 (en) | 2004-09-13 | 2011-12-08 | Morningside Venture Investments Limited | Biosynchronous transdermal drug delivery |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| WO2006069008A1 (en) * | 2004-12-22 | 2006-06-29 | Vesta Medical, Llc | Compositions and devices for inactivation of pharmaceuticals to facilitate waste disposal, and methods thereof |
| US20070014839A1 (en) * | 2005-07-18 | 2007-01-18 | Stefan Bracht | Decomposer film for transdermal patches |
| AU2006326377B2 (en) * | 2005-12-13 | 2010-10-07 | Biodelivery Sciences International, Inc. | Abuse resistant transmucosal drug delivery device |
| SI2054031T1 (sl) | 2006-07-21 | 2016-09-30 | Biodelivery Sciences International, Inc. | Transmukozne naprave za administracijo z izboljšanim vnosom |
| US20080226702A1 (en) * | 2007-03-16 | 2008-09-18 | Endo Pharmaceuticals, Inc. | Transdermal Delivery Form Disposal Systems and Methods |
| WO2009106831A2 (en) | 2008-02-28 | 2009-09-03 | Syntropharma Limited | Pharmaceutical composition |
| JP2011515495A (ja) * | 2008-03-26 | 2011-05-19 | オールトランツ インコーポレイティド | オピエートアゴニスト及びアゴニスト−アンタゴニストの乱用抑制経皮製剤 |
| DE202008004785U1 (de) * | 2008-04-04 | 2009-08-13 | Grünenthal GmbH | Entsorgungsvorrichtung |
| US8329210B2 (en) * | 2008-09-23 | 2012-12-11 | Pharmapatch, Llc | Twin transdermal drug delivery patch |
| TWI630208B (zh) | 2008-12-08 | 2018-07-21 | 歐陸斯迪公司 | 二氫羥戊甲嗎啡 |
| US8507182B2 (en) * | 2009-06-09 | 2013-08-13 | Eastman Kodak Company | Method of providing lithographic printing plates |
| DE102009036485B4 (de) * | 2009-08-07 | 2012-10-04 | Lts Lohmann Therapie-Systeme Ag | Mittel zur zerstörenden Entsorgung von medizinischen Wirkstoffen in transdermalen therapeutischen Systemen |
| EP2552245B1 (en) | 2010-03-26 | 2018-11-14 | Philip Morris Products S.A. | Inhibition of sensory irritation during consumption of non-smokeable tobacco products |
| US8952038B2 (en) | 2010-03-26 | 2015-02-10 | Philip Morris Usa Inc. | Inhibition of undesired sensory effects by the compound camphor |
| EP2729148A4 (en) | 2011-07-06 | 2015-04-22 | Parkinson S Inst | COMPOSITIONS AND METHOD FOR THE TREATMENT OF SYMPTOMS IN PATIENTS WITH MORBUS PARKINSON |
| SG10201610097WA (en) | 2011-08-18 | 2017-01-27 | Biodelivery Sciences Int Inc | Abuse-resistant mucoadhesive devices for delivery of buprenorphine |
| CN103764092A (zh) | 2011-09-30 | 2014-04-30 | 帝国制药美国公司 | 普通药物处置系统 |
| CN103764129A (zh) * | 2011-09-30 | 2014-04-30 | 帝国制药美国公司 | 透皮贴剂处置系统 |
| US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
| GB201309654D0 (en) | 2013-05-30 | 2013-07-17 | Euro Celtique Sa | Method |
| JP2018511355A (ja) | 2015-01-28 | 2018-04-26 | クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 薬剤送達方法及びシステム |
| JP6980533B2 (ja) | 2015-02-19 | 2021-12-15 | キャンデサント・バイオメディカル・インコーポレイテッドCandesant Biomedical, Inc. | 熱を発生させるための医療用デバイスおよびこれを用いた治療方法 |
| JP2018511127A (ja) | 2015-03-12 | 2018-04-19 | クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 渇望入力及び支援システム |
| GB201520390D0 (en) * | 2015-11-19 | 2016-01-06 | Euro Celtique Sa | Composition |
| US20170273974A1 (en) | 2016-03-24 | 2017-09-28 | Medrx Co., Ltd | Patch preparations with misuse prevention features |
| JPWO2017164084A1 (ja) | 2016-03-24 | 2019-02-07 | 株式会社 メドレックス | 誤用防止特性を有する貼付製剤 |
| CA2972220C (en) * | 2016-06-29 | 2023-01-24 | Disposerx, Inc. | Disposal of medicaments |
| EP3565617A1 (en) | 2017-01-06 | 2019-11-13 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
| US11510882B2 (en) | 2017-09-22 | 2022-11-29 | Medrx Co., Ltd. | Non-readherable adhesive patch |
| US11389844B2 (en) | 2018-03-20 | 2022-07-19 | Verde Environmental Technologies, Inc. | Blister pack disposal system |
| AU2019279884B2 (en) | 2018-05-29 | 2025-01-30 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| CA3119992A1 (en) | 2018-11-16 | 2020-05-22 | Morningside Venture Investments Limited | Thermally regulated transdermal drug delivery system |
| MX2022006618A (es) | 2019-12-10 | 2022-06-24 | Candesant Biomedical Inc | Dispositivos medicos para generar calor y metodos de tratamiento que usan los mismos. |
| EP4403205A3 (en) * | 2019-12-10 | 2024-08-07 | Candesant Biomedical, Inc. | Methods and systems for disposing alkali metal patches |
| CN119588727B (zh) * | 2024-12-06 | 2025-09-26 | 奕瑞新材料科技（太仓）有限公司 | 一种碘化铯闪烁屏用激活剂提纯系统、提纯方法及应用 |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3527864A (en) | 1966-11-18 | 1970-09-08 | Procter & Gamble | Compositions for topical application to animal tissue and method of enhancing penetration thereof |
| US3540580A (en) * | 1967-07-03 | 1970-11-17 | Borden Inc | Heat-seal adhesive and package |
| US3472931A (en) | 1969-01-17 | 1969-10-14 | Foster Milburn Co | Percutaneous absorption with lower alkyl amides |
| US3903256A (en) | 1972-02-07 | 1975-09-02 | Procter & Gamble | Compositions for topical application of animal tissue and method of enhancing penetration thereof |
| US3896238A (en) | 1972-04-05 | 1975-07-22 | Procter & Gamble | Dermatological compositions |
| US3952099A (en) | 1973-03-13 | 1976-04-20 | The Procter & Gamble Company | Dermatological compositions |
| US4046886A (en) | 1975-01-17 | 1977-09-06 | The Procter & Gamble Company | Dermatological compositions |
| US4405616A (en) | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
| US4316893A (en) | 1975-06-19 | 1982-02-23 | Nelson Research & Development Co. | Vehicle composition containing 1-substituted azacycloalkan-2-ones |
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4130667A (en) | 1976-01-12 | 1978-12-19 | The Procter & Gamble Company | Dermatological compositions |
| US4060084A (en) | 1976-09-07 | 1977-11-29 | Alza Corporation | Method and therapeutic system for providing chemotherapy transdermally |
| US4335115A (en) | 1976-11-01 | 1982-06-15 | The Procter & Gamble Company | Anti-acne composition |
| US4166058A (en) * | 1978-08-11 | 1979-08-28 | The Goodyear Tire & Rubber Company | Heat sensitive primer exhibiting color change and containing a resin blend, elemental sulfur, and a dye |
| US4326566A (en) | 1979-09-11 | 1982-04-27 | N. V. Weefautomaten Picanol | Color selector |
| US4299826A (en) | 1979-10-12 | 1981-11-10 | The Procter & Gamble Company | Anti-acne composition |
| US4248748A (en) * | 1980-02-04 | 1981-02-03 | Minnesota Mining And Manufacturing Company | Heat-activated adhesive |
| DE3047635A1 (de) * | 1980-12-17 | 1982-07-22 | Hilti AG, 9494 Schaan | Klebeverfahren mittels schmelzklebstoff sowie mittel zur durchfuehrung des verfahrens |
| US4379454A (en) | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
| US4343798A (en) | 1981-06-23 | 1982-08-10 | The Procter & Gamble Company | Topical antimicrobial anti-inflammatory compositions |
| US4560553A (en) | 1981-07-07 | 1985-12-24 | Merck & Co., Inc. | Use of eucalyptol for enhancing skin permeation of bio-affecting agents |
| US4510621A (en) * | 1983-06-30 | 1985-04-09 | Arvey Corporation | Self-sealing pouch for forming adhesive-to-adhesive seal |
| US4588580B2 (en) * | 1984-07-23 | 1999-02-16 | Alaz Corp | Transdermal administration of fentanyl and device therefor |
| JPS61103840A (ja) | 1984-10-26 | 1986-05-22 | Nitto Electric Ind Co Ltd | 外皮投与用組成物 |
| US4806341A (en) | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
| US5066648A (en) | 1985-11-29 | 1991-11-19 | Merck & Co., Inc. | Pyroglutamic acid esters used as dermal penetration enhancers for drugs |
| US4973968A (en) | 1986-03-07 | 1990-11-27 | Plessey Overseas Limited | Radar system for determining first time around targets from multiple time around targets |
| US4863970A (en) | 1986-11-14 | 1989-09-05 | Theratech, Inc. | Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols |
| US4940586A (en) | 1987-02-26 | 1990-07-10 | Alza Corporation | Skin permeation enhancer compositions using sucrose esters |
| US4746515A (en) | 1987-02-26 | 1988-05-24 | Alza Corporation | Skin permeation enhancer compositions using glycerol monolaurate |
| US4879275A (en) | 1987-09-30 | 1989-11-07 | Nelson Research & Development Co. | Penetration enhancers for transdermal delivery of systemic agent |
| US5225473A (en) * | 1987-11-25 | 1993-07-06 | Minnesota Mining And Manufacturing Company | Pressure-sensitive adhesives |
| GB8811669D0 (en) * | 1988-05-17 | 1988-06-22 | Alcan Int Ltd | Colour-changeable adhesive |
| US5164406A (en) | 1988-06-02 | 1992-11-17 | Bristol-Myers Squibb Co. | Method for enhancing transdermal penetration and compositions useful therein |
| US5641504A (en) | 1988-06-09 | 1997-06-24 | Alza Corporation | Skin permeation enhancer compositions using glycerol monolinoleate |
| US5378730A (en) | 1988-06-09 | 1995-01-03 | Alza Corporation | Permeation enhancer comprising ethanol and monoglycerides |
| US4960771A (en) | 1988-07-12 | 1990-10-02 | Rajadhyaksha Vithal J | Oxazolidinone penetration enhancing compounds |
| US5236714A (en) | 1988-11-01 | 1993-08-17 | Alza Corporation | Abusable substance dosage form having reduced abuse potential |
| US4956171A (en) * | 1989-07-21 | 1990-09-11 | Paco Pharmaceutical Services, Inc. | Transdermal drug delivery using a dual permeation enhancer and method of performing the same |
| US5750134A (en) | 1989-11-03 | 1998-05-12 | Riker Laboratories, Inc. | Bioadhesive composition and patch |
| US5240711A (en) | 1989-11-29 | 1993-08-31 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system comprising as active component buprenorphine |
| US5069909A (en) | 1990-06-20 | 1991-12-03 | Cygnus Therapeutic Systems | Transdermal administration of buprenorphine |
| JP3196851B2 (ja) * | 1991-04-01 | 2001-08-06 | 積水化学工業株式会社 | 医療用貼付剤 |
| US5227169A (en) | 1991-05-17 | 1993-07-13 | Theratech, Inc. | Sorbitan esters as skin permeation enhancers |
| US5308887A (en) * | 1991-05-23 | 1994-05-03 | Minnesota Mining & Manufacturing Company | Pressure-sensitive adhesives |
| US5149538A (en) | 1991-06-14 | 1992-09-22 | Warner-Lambert Company | Misuse-resistive transdermal opioid dosage form |
| US5981666A (en) * | 1991-07-12 | 1999-11-09 | Adhesives Research, Inc. | Method for the production of a high performance pressure sensitive adhesive |
| US5232702A (en) * | 1991-07-22 | 1993-08-03 | Dow Corning Corporation | Silicone pressure sensitive adhesive compositons for transdermal drug delivery devices and related medical devices |
| US5238933A (en) | 1991-10-28 | 1993-08-24 | Sri International | Skin permeation enhancer compositions |
| US5229130A (en) | 1991-12-20 | 1993-07-20 | Cygnus Therapeutics Systems | Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems |
| CA2097163C (en) | 1992-06-01 | 2002-07-30 | Marianna Foldvari | Topical patch for liposomal drug delivery system |
| US5308625A (en) | 1992-09-02 | 1994-05-03 | Cygnus Therapeutic Systems | Enhancement of transdermal drug delivery using monoalkyl phosphates and other absorption promoters |
| US6162456A (en) | 1992-09-24 | 2000-12-19 | Ortho-Mcneil Pharmaceutical, Inc. | Adhesive transdermal drug delivery matrix of a physical blend of hydrophilic and hydrophobic polymers |
| JPH0710742Y2 (ja) * | 1993-02-05 | 1995-03-15 | 日本臓器製薬株式会社 | 救急絆創膏 |
| DK0695177T3 (da) * | 1993-04-20 | 1998-09-28 | Hexal Ag | Plaster indeholdende aktivt stof |
| US5520385A (en) * | 1993-07-30 | 1996-05-28 | Composite Development Corporation | Article assembled with thermoreponsive material and method |
| EP0721348B1 (en) | 1993-09-29 | 1999-09-01 | Alza Corporation | Monoglyceride/lactate ester permeation enhancer |
| US5470529A (en) * | 1994-03-08 | 1995-11-28 | Sumitomo Metal Industries, Ltd. | High tensile strength steel sheet having improved formability |
| US5420106A (en) | 1994-03-22 | 1995-05-30 | Bristol-Myers Squibb Company | Method and composition having enhanced alpha-hydroxy acid skin permeation and retention |
| JP2819236B2 (ja) * | 1994-05-06 | 1998-10-30 | 日東電工株式会社 | 経皮吸収製剤 |
| US5540934A (en) | 1994-06-22 | 1996-07-30 | Touitou; Elka | Compositions for applying active substances to or through the skin |
| GB9425783D0 (en) * | 1994-12-21 | 1995-02-22 | Ethical Pharma Ltd | Packaging of patches |
| US5573778A (en) | 1995-03-17 | 1996-11-12 | Adhesives Research, Inc. | Drug flux enhancer-tolerant pressure sensitive adhesive composition |
| US5882676A (en) | 1995-05-26 | 1999-03-16 | Alza Corporation | Skin permeation enhancer compositions using acyl lactylates |
| US5785991A (en) | 1995-06-07 | 1998-07-28 | Alza Corporation | Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate |
| EP0752421B1 (en) | 1995-07-07 | 2005-10-12 | AstraZeneca AB | Ortho-substituted aromatic compounds, containing three (het)aryl moieties, their preparation and their use as prostaglandin E2-(PGE2)-antagonists |
| AU6657396A (en) * | 1995-07-28 | 1997-02-26 | Novartis Ag | Transdermal system |
| US5902603A (en) | 1995-09-14 | 1999-05-11 | Cygnus, Inc. | Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use |
| US5837289A (en) | 1996-07-23 | 1998-11-17 | Grasela; John C. | Transdermal delivery of medications using a combination of penetration enhancers |
| EP0934078B1 (en) | 1996-10-24 | 2002-12-18 | Alza Corporation | Permeation enhancers for transdermal drug delivery compositions, devices, and methods |
| US5952000A (en) | 1996-10-30 | 1999-09-14 | Theratech, Inc. | Fatty acid esters of lactic acid salts as permeation enhancers |
| DE19649534B4 (de) * | 1996-11-29 | 2004-05-06 | Lts Lohmann Therapie-Systeme Ag | Verpackung aus Verbundpackstoff zum Verpacken von wirkstoffhaltigen Pflastern |
| US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
| US5804215A (en) * | 1997-03-21 | 1998-09-08 | L. Perrigo Company | Transdermal patch disposal system and method |
| US6017983A (en) * | 1998-01-29 | 2000-01-25 | Alpha Metals, Inc. | Color indicator for completion of polymerization for thermosets |
| DE19901085C2 (de) * | 1999-01-14 | 2003-12-18 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit einer selbstklebenden Matrix, enthaltend organische Säure-Additionssalze von Alkaloiden des Morphin- bzw. Morphinantyps |
| US7018649B2 (en) * | 2000-10-23 | 2006-03-28 | Euro-Celtique, S.A. | Felodipine transdermal device and methods |
| US6682757B1 (en) * | 2000-11-16 | 2004-01-27 | Euro-Celtique, S.A. | Titratable dosage transdermal delivery system |
| WO2002085268A1 (en) * | 2001-04-23 | 2002-10-31 | Euro-Celtique S.A. | Disposal system for transdermal dosage form |
| ES2377672T3 (es) * | 2001-05-01 | 2012-03-29 | Euro-Celtique S.A. | Sistemas transdérmicos resistentes al abuso que contienen opioides |
| US6638981B2 (en) * | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
-
2003
- 2003-06-10 NZ NZ537180A patent/NZ537180A/en not_active IP Right Cessation
- 2003-06-10 EP EP10010605A patent/EP2298302A1/en not_active Ceased
- 2003-06-10 EP EP07003694A patent/EP1837023A1/en not_active Ceased
- 2003-06-10 CN CNB038135558A patent/CN100525767C/zh not_active Expired - Fee Related
- 2003-06-10 DK DK03757468T patent/DK1513532T3/da active
- 2003-06-10 KR KR1020117022754A patent/KR20110120358A/ko not_active Ceased
- 2003-06-10 EA EA200401564A patent/EA007240B1/ru not_active IP Right Cessation
- 2003-06-10 SI SI200330785T patent/SI1513532T1/sl unknown
- 2003-06-10 DE DE60312160T patent/DE60312160T2/de not_active Expired - Lifetime
- 2003-06-10 EP EP03757468A patent/EP1513532B1/en not_active Expired - Lifetime
- 2003-06-10 EP EP10179056A patent/EP2266565A1/en not_active Ceased
- 2003-06-10 ES ES03757468T patent/ES2283812T3/es not_active Expired - Lifetime
- 2003-06-10 CN CN200810170710.3A patent/CN101455649B/zh not_active Expired - Fee Related
- 2003-06-10 CA CA2488915A patent/CA2488915C/en not_active Expired - Fee Related
- 2003-06-10 PT PT03757468T patent/PT1513532E/pt unknown
- 2003-06-10 US US10/457,562 patent/US20040033255A1/en not_active Abandoned
- 2003-06-10 AT AT03757468T patent/ATE355061T1/de active
- 2003-06-10 AU AU2003251482A patent/AU2003251482A1/en not_active Abandoned
- 2003-06-10 JP JP2004510792A patent/JP4949625B2/ja not_active Expired - Fee Related
- 2003-06-10 KR KR1020047020117A patent/KR101407131B1/ko not_active Expired - Fee Related
- 2003-06-10 WO PCT/US2003/018256 patent/WO2003103673A1/en not_active Ceased
- 2003-06-10 MX MXPA04012333A patent/MXPA04012333A/es active IP Right Grant
- 2003-10-06 UA UAA200500155A patent/UA82194C2/uk unknown
-
2004
- 2004-11-24 ZA ZA200409495A patent/ZA200409495B/xx unknown
- 2004-12-02 IL IL16551704A patent/IL165517A0/xx unknown
-
2005
- 2005-01-10 NO NO20050126A patent/NO334455B1/no not_active IP Right Cessation
-
2007
- 2007-05-17 CY CY20071100668T patent/CY1107630T1/el unknown
-
2008
- 2008-07-15 US US12/173,451 patent/US20080274168A1/en not_active Abandoned
-
2009
- 2009-09-18 AU AU2009217420A patent/AU2009217420B2/en not_active Ceased
-
2010
- 2010-07-12 JP JP2010158074A patent/JP5507367B2/ja not_active Expired - Lifetime
-
2014
- 2014-01-08 JP JP2014001693A patent/JP5898242B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014088422A5 (enExample) | ||
| JP2010189403A5 (enExample) | ||
| CO6150130A2 (es) | Liberacion controlada de formulaciones y metodos asociados | |
| JP2012519675A5 (enExample) | ||
| JP2011515495A5 (enExample) | ||
| JP2011126895A5 (enExample) | ||
| RU2011135568A (ru) | Защищенная от применения не по назначению экструдированная из расплава композиция с уменьшенным взаимодействием со спиртом | |
| HRP20150835T1 (hr) | Farmaceutski oblici doziranja s kontroliranim oslobađanjem | |
| JP2014510094A5 (enExample) | ||
| RU2009101082A (ru) | Фармацевтические композиции | |
| JP2009541320A5 (enExample) | ||
| RU2010106202A (ru) | Составы неопиоидных и ограниченных опиоидных аналгетиков | |
| US20060073102A1 (en) | Abuse-resistant opioid solid dosage form | |
| HRP20120641T1 (hr) | Oralni farmaceutski oblici doziranja otporni na neovlašteno korištenje koji sadrže opioidni analgetik | |
| CA2640339A1 (en) | Tamper resistant opioid dosage forms | |
| JP2010511683A5 (enExample) | ||
| CA2547334A1 (en) | Methods and compositions for deterring abuse of opioid containing dosage forms | |
| JP2009545561A5 (enExample) | ||
| RU2013126476A (ru) | Лечение зависимости и расстройства побуждений с применением ингибиторов фдэ7 | |
| JP2008528534A5 (enExample) | ||
| JP2008534564A5 (enExample) | ||
| JP2011519930A5 (enExample) | ||
| TWI522101B (zh) | 處理由類鴉片引起之不利的藥效動力反應之系統和方法 | |
| WO2007088489A2 (en) | Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same | |
| NZ589627A (en) | Pharmaceutical compositions comprising an opioid and a 4-(2-furanyl)thiazole compound for suppressing undesirable effects of opioids |